Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer

1. Vuky, J.
2. Balar, A.V.
3. Castellano, D.
4. O’Donnell, P.H.
5. Grivas, P.
6. Bellmunt, J.
7. Powles, T.
8. Bajorin, D.
9. Hahn, N.M.
10. Savage, M.J.
11. Fang, X.
12. Godwin, J.L.
13. Frenkl, T.L.
14. Moreno, B.H.
15. de Wit, R.
16. Plimack, E.R.